Home > Article > The MyVal Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis – Current Evidence and Future Directions
Interventional Cardiology
Read Time: < 1 min

The MyVal Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis – Current Evidence and Future Directions

Published Online: December 23rd 2020 Heart International. 2020;14(2):Online ahead of journal publication
Authors: Gunasekaran Sengottovelu, Vijay Kumar, Ashok Seth
Quick Links:
Article Information

Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The MyVal™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical feature of this transcatheter valve, pre-clinical studies, and evidence from the first in-human trial. We also provide a brief overview of planned clinical trials and registries.


Transcatheter aortic valve implantation, balloon-expandable, transcatheter heart valve, newer-generation transcatheter heart valve, severe aortic stenosis


**This manuscript has been accepted for publication, but may be subject to minor changes during the production process.**

Article Information:

Gunasekaran Sengottovelu is a proctor for Myval THV, and has received honoraria fromMeril Life Sciences Pvt. Ltd., India. Ashok Seth is an external scientific advisor to Meril Life Sciences Pvt. Ltd., India; a principal investigator of MyVal- 1Study; and a proctor for MyVal THV. Vijay Kumar has no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.


Ashok Seth, Fortis Escorts Heart Institute, New Delhi -110025, India. E: ashok.seth@fortishealthcare.com


Support: No funding was received in the publication of this article.

Open Access

This article is freely accessible at touchCARDIO.com © Touch Medical Media 2020.



Further Resources

Share this Article
Related Content In Interventional Cardiology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar